Trial Profile
A randomized, double blind, comparative, phase II/III study to evaluate the immunogenicity and safety of three formulations (15mcg without adjuvant and 7.5mcg with adjuvant and 3.75mcg with adjuvant) of monovalent H1N1 influenza A (2009) virus vaccine in healthy adults. - H1N1 Adult
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 21 Jan 2019
Price :
$35
*
At a glance
- Drugs Influenza A virus vaccine-H1N1 (Primary) ; Adjuvants
- Indications Influenza A virus H1N1 subtype
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Panacea Biotec
- 21 Aug 2010 Status changed from active, no longer recruiting to completed as reported by Clinical Trials Registry - India record.